Novavax, Inc. is a clinical-stage biopharmaceutical company, which engages in development of novel recombinant vaccines to address a broad read more
Gregory Glenn M.D. ā President of Research & Development at Novavax
Executive Bio
Dr. Gregory M. Glenn, also known as Greg, M.D., has been the President of Research & Development at Novavax, Inc. since March 2016. Dr. Glenn served as Senior Vice President of Research and Development at Novavax, Inc. from January 2014 to March 2016. Dr. Glenn Co-founded Intercell USA, Inc. (also known as Iomai Corporation) and served as its Senior Vice President and Chief Scientific Officer since September 1997. Dr. Glenn served as Senior Vice President of Research and Development at Novavax, Inc. since January 13, 2014. Dr. Glenn served as the Chief Medical Officer and Senior Vice President at Novavax, Inc. Dr. Glenn served as the Chief Scientific Officer of Novavax, Inc. since July 2010. Dr. Glenn is a pediatrician who practiced general pediatrics in primary care settings prior to moving to the WRAIR and was an attending physician at Walter Reed. Since 1997, he has been responsible for the conception, implementation and development of the basic science and early clinical trials. He was attached to the Institute for 6 years as a Member of the Department of Membrane Biochemistry. At Oral Roberts University School of Medicine, Dr. Glenn received the Pediatrics Award and Dean's Award for Academic Excellence. Dr. Glenn is a pioneer in vaccine delivery and adjuvants and has brought several products from concept into clinical development including the travelers' diarrhea vaccine patch and an adjuvant patch for a pandemic influenza vaccine, developed under U.S. government contracts. He has co-authored more than 150 research publications, scientific abstracts and presentations and successful grant applications and holds multiple U.S., European and other international patents. He has published 7 articles and 2 book chapters describing Transcutaneous Immunization. He was an associate in international health at Johns Hopkins University's School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research. In addition, he is an associate editor of the journals Expert Review of Vaccines and Human Vaccine and was a board-certified pediatrician. Dr. Glenn completed the Medical Research Fellowship at the Walter Reed Army Institute of Research (WRAIR). He continues his research at WRAIR under a CRDA. Dr. Glenn received his BA in biology and chemistry from Whitman College and his MD from Oral Roberts University School of Medicine.
Key Executives
Name
Title
Salary
Total Comp Total Compensation includes both short-term and long-term benefits, option grants, salary, bonuses, company perks, etc. that can be used to determine financial benefits. An executive may or may not realize all of the Total Co mpensation during their tenure at the Company. Values of the benefits may change over time.
Executive Team Culture Ratings from Novavax Employees
BOTTOM
35%
Novavax's Executive Team scores in the Bottom 35%
of similar sized companies on Comparably
of similar sized companies on Comparably
Not Enough Ratings To Show Who Ranks Executive Team the Highest
Anonymously rate my experience at NovavaxNot Enough Ratings To Show Who Ranks Executive Team the Lowest
Anonymously rate my experience at NovavaxNovavax's Executive Team at a Glance
Based on 7 ratings, Novavax's employees are less satisfied with their Executive Team and give them a āC-ā or 62/100.
Novavax's Executive Team ranks in the Bottom 35% of other companies in Washington, DC and Bottom 35% of other companies on Comparably that also have 201-500 Employees.
×